Claims for Patent: 9,789,184

Summary for Patent: 9,789,184

Title:	Anti-EGFR antibodies and uses thereof
Abstract:	The present invention provides antibodies that bind to EGFR and methods of using same. According to certain embodiments of the invention, the antibodies are fully human antibodies that bind to human EGFR with high affinity. In certain embodiments, the antibodies of the present invention are capable of inhibiting the growth of tumor cells expressing high levels of EGFR and/or inducing antibody-dependent cell-mediated cytotoxicity (ADCC) of such cells. The antibodies of the invention are useful for the treatment of various cancers as well as other EGFR-related disorders.
Inventor(s):	Daly; Christopher (New York, NY), Thurston; Gavin (Briarcliff Manor, NY), Papadopoulos; Nicholas J. (LaGrangeville, NY)
Assignee:	Regeneron Pharmaceuticals, Inc. (Tarrytown, NY)
Application Number:	14/820,324
Patent Claims:	1. A method for inhibiting tumor growth, the method comprising administering to a subject afflicted with a tumor a pharmaceutical composition comprising an antibody or antigen-binding fragment thereof that specifically binds human epidermal growth factor receptor (hEGFR), wherein the antibody or antigen-binding fragment thereof comprises: (a) the complementarity determining regions (CDRs) of a heavy chain variable region (HCVR) comprising the amino acid sequence of SEQ ID NO:130, and (b) the CDRs of a light chain variable region (LCVR) comprising the amino acid sequence of SEQ ID NO:138. 2. The method of claim 1, wherein the antibody or antigen-binding fragment thereof comprises the heavy and light chain CDRs of a HCVR/LCVR amino acid sequence pair having SEQ ID NOs: 130/138. 3. The method of claim 2, wherein the antibody or antigen-binding fragment thereof comprises HCDR1, HCDR2, HCDR3, LCDR1, LCDR2, and LCDR3 domains, respectively, having SEQ ID NOs: 132, 134, 136, 140, 142, and 144. 4. The method of claim 1, wherein the tumor is selected from the group consisting of a renal tumor, a pancreatic tumor, a head and neck tumor, a breast tumor, a prostate tumor, a colon tumor, a gastric tumor, an ovarian tumor, a lung tumor, and a skin tumor. 5. The method of claim 1, further comprising administering to the subject a second therapeutic agent. 6. The method of claim 5, wherein the second therapeutic agent is an antibody or antigen-binding fragment thereof that specifically binds HER2, ErbB3, ErbB4, cMet, IGF1R, Ang2, PDGFR-.alpha. or PDGFR-.beta.. 7. The method of claim 5, wherein the second therapeutic agent is a VEGF antagonist. 8. The method of claim 7, wherein the VEGF antagonist is a VEGF-Trap. 9. The method of claim 7, wherein the VEGF antagonist is an anti-VEGF antibody. 10. The method of claim 9, wherein the anti-VEGF antibody is bevacizumab. 11. The method of claim 7, wherein the VEGF antagonist is a small molecule kinase inhibitor of VEGF receptor. 12. The method of claim 11, wherein the small molecule kinase inhibitor of VEGF receptor is sunitinib, sorafenib or pazopanib. 13. The method of claim 1, wherein the antibody or antigen-binding fragment thereof is administered as part of a treatment regimen that also includes radiation treatment and/or conventional chemotherapy.

Details for Patent 9,789,184

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Genentech, Inc.	AVASTIN	bevacizumab	Injection	125085	02/26/2004		2032-06-25